PATENT

Case Docket No. ACADIA.030A
Date: April 14, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Weiner, et al.
Appl. No.	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Unknown
Group Art Unit	:	Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 14, 2004
(Date)

Sam K. Tahmassebi, Reg. No. 45,151

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with thirty-seven (37) references.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\REM\REM-1258.DOC:sad
041404

INFORMATION DISCLOSURE STATEMENT

Applicant	:	Weiner, et al.
App. No.	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Unknown
Group Art Unit	:	Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 37 references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 14, 2004

By: _____

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\REM\REM-1257.DOC:sad
041404

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.030A	APPLICATION NO. 10/759,561
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Weiner, et al.	
	FILING DATE January 15, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,707,798	01/13/98	Brann			
	2	5,912,132	06/15/99	Brann			
	3	5,955,281	09/21/99	Brann			
	4	2002/0004513	01/10/02	Andersson et al.			
	5	6,358,698	03/19/02	Weiner et al.			

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	6	Barnes, N.M., et al., "A review of central 5-HT receptors and their fuction," *Neuropharmacology,* 38:1083-1152 (1999)
	7	Barr, A.J., et al., "Agonist-independent Activiation of G_z by the 5-Hydroxytryptamine$_{1A}$ Receptor Co-expressed in *Spodoptera frugiperda* Cells," *J. Biol. Chem.* 272:32979-87 (1997).
	8	Bennett, J., P., Landow, E., R., and Shuh, L., A. (1993) "Suppression of dyskinesias in advanced Parkinson's Disease. II Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms," *Neurology,* **43:** 1551-1555.
	9	Bibbiani, F., Oh, F., D., and Chase, T., C. (2001) "Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models," *Neurology,* **57:** 1829-1834.
	10	Bond, et al., "Physiological effects of inverse agonists in transgenic mice with myocardial overexpresion of the β_2-adrenoceptor," *Nature* 374:272 (1995).
	11	Brann, "Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes," *Chem. Abstr.* 128:111548 (1998) and citations therein.
	12	Butcher, L., Engel, J., and Fuxe, K. (1970) "L-Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition," *J. Pharm. Pharmac.,* **22**: 313-316.
	13	Cerione et al., "The Mammalian β_2-Adrenergic Receptor: Reconstitution of Functional Interactions between Pure Receptor and Pure Stimulatory Nucleotide Binding Protein of the Adenylate Cyclase System," *Biochemistry* 23:4519-25 (1984)
	14	Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A., M., and Agid, Y. (1997) "Low-dose clozapine improves dyskinesias in Parkinson's disease," *Neurology,* **48:** 658-662.
	15	Everett, G., M., and Borcherding, J., W. (1970) "L-dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice," *Nature,* **168:** 849-850.
	16	The French Clozapine Study Group (1999) "Clozapine in drug-induced psychosis in Parkinson's disease," *Lancet,* **353**: 2041-2042.
	17	Friedman, J., H., and Factor, S., A. (2000) "Atypical Antipsychotics in the Treatment of Drug-Induced Psychosis in Parkinson's Disease," *Mov. Disord,* **15(2):** 201-211.
	18	Fuller, R.W., "Drugs Acting on Serotonergic Neuronal Systems," *Biology of Serotonergic Transmission,* 1982, pp. 221-247.

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.030A	APPLICATION NO. 10/759,561
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Weiner, et al.	
	FILING DATE January 15, 2004	GROUP Unknown

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	19	Gamma, A., Buck, A., Berthold, T., Liechti, M., E., and Vollenweider, F., X. (2000) "3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [$H_2{}^{15}O$]-PET in Healthy Humans," *Neuropsychopharmacology,* **23(4):** 388-395.
	20	Gershon, et at, "5-Hydroxytryptamine and enteric neurones," The *Peripheral Actions of 5-Hydroxytryptamine,* pp. 247-273 (1989)
	21	Glennon, "Serotonin Receptors: Clinical Implications," *Neurosci. Biobehavioral Rev.,* 14:35-47 (1990)
	22	Julius et al., "The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors," *Proc. Natl. Acad. Sci. USA* 87:928-932
	23	Leysen, J., E., Niemegeers, C., J., Tollenaraere, J., P., and Laduron, P., M. (1978) "Serotonergic component of neuroleptic receptors," *Nature (Lond)* **272:** 168-171.
	24	Liechti, M., E., Geyer, M., A., Hell, D., and Vollenwieder, F., X. (2001) "Effects of MDMA(ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin," *Neuropsychopharmacology,* **24(3):** 240-252.
	25	Linder, "Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency," *Clin. Chem.* 43:254-66 (1997)
	26	Meltzer, "The Role of Serotonin in Antipsychotic Drug Action," *Neuropsychopharmacology,* 21:l06S-l15S (1999)
	27	Meltzer, H., Y., Kennedy, J., Dai, J., Parsa, M., and Riley, D. (1995) "Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease. A High Potency Effect of Clozapine," *Neuropsychopharmacology,* **12(1):** 39-45.
	28	Moulignier, A., "Récepteurs Centraux de la Sérotonine Principaux Aspects Fondamentaux et fonctionnels Applications Thérapeutiques," *Rev. Neurol.* 150:3-15, (1994)
	29	Ng, K., Y., Chase, T., N., Colburn, R., W., and Kopin, I., J., (1970) "L-Dopa Induced Release of Cerebral Monoamines," *Science,* **170:** 76-77.
	30	Nordstrom, A., L., Farde, L., and Halldin, C. (1993) "High 5-HT2 receptor occupancy in clozapine treated patients as demonstrated by PET," *Psychopharmacology,* **110(3):** 365-367.
	31	Pace et al., "A mutant α subunit of G_{12} induces neoplastic transformation of Rat-1 cells," *Proc. Natl. Acad. Sci. USA* 88:7031-35 (1991)
	32	The Parkinson Study Group (1999) "Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease," *New Eng. J. Med.,* **340(10):** 757-763.
	33	Sadzot, B., Baraban, J., M., Glennon, R., A., Lyon, R., A., Leonhardt, S., Jan, C., R., and Tietler, M. (1989) "Hallucinogenic drug interactions at human brain 5-HT_2 receptors; implications for treating LSD-induced hallucinogenesis," *Psychopharmacology,* **98(4):** 495-499.
	34	Saltzman et al., "Cloning of the Human Serotonin 5-HT2 and 5-HT1C Receptor Subtypes," *Biochem. Biophys. Res. Comm.* 181:1469-78
	35	Saxena, et al, "Cardiovascular Effects of Serotonin Agonists and Antagonists," *J. Cardiovascular Pharmacol.* 15: Supp. 7 (1990), pages S17-S34.
	36	Vallar et al., "Altered G_s and adenylate cyclase activity in human GH-secreting pituitary adenomas," *Nature* 330:556-58 (1987)
	37	Weiner, D., M., Burstein, E., S., Nash, N., Croston, G., E., Currier, E., A., Vanover, K., E., Harvey, S., C., Donohue, E., Hansen, H., C., Andersson, C., M., Spalding, T., A., Gibson, D., F., Krebs-Thomson, K., Powell, S., B., Geyer, M., A., Hacksell, U., and Brann, M., R. (2001) "5-Hydroxytryptamine$_{2A}$ Receptor Inverse Agonists as Antipsychotics," *J Pharmacol Exp Ther.,* **299(1):** 268-76.

S:\DOCS\REM\REM-1255.DOC:sad:041404

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.